Contingency management, often shortened to CM, is a structured treatment approach that uses incentives linked to clearly defined, verified behaviors. In substance use care, the target may concern substance-related results or another treatment behavior, depending on the evidence-based program being used. The important distinction is that the rules are planned, explained, and applied consistently. An occasional gift for doing well is not enough to establish that a service provides clinical CM.

For someone with co-occurring mental health and substance use disorders, CM should connect with the rest of treatment. It can address a specific behavioral target while psychiatric care, appropriate medication, therapy, and practical support continue. Ask the clinician why CM is being proposed, which outcome it is intended to support, and how its structure fits your circumstances.

What is the target, and why was it chosen?

Ask the program to describe the target in plain language. Is it related to a particular substance, attendance, or another defined action? How does that target connect to your care plan? A person may have several needs, but the incentive system should not be so vague that success depends on a staff member’s general impression of attitude or motivation.

The SAMHSA guide to stimulant treatment describes CM as an evidence-based behavioral approach. Evidence is particularly relevant in stimulant use disorder treatment, but that does not establish the same result for every substance, psychiatric condition, or program design. Ask the clinician to connect the evidence to the actual target being proposed.

If you have several substance use concerns, clarify which are included and how the others are treated. A result related to one substance does not establish that every medical or psychiatric risk has resolved. The incentive target is one part of care, not a complete measure of health or recovery. The wider plan should remain visible at review appointments.

How does the program work in practice?

Request an explanation of the schedule, verification process, incentive type, and duration. Ask when a result is reviewed and when the incentive is provided. If the rules change as the program progresses, those changes should be described in advance. You should not have to infer the system from another participant’s experience or an informal conversation at reception.

SAMHSA’s January 2025 CM advisory emphasizes evidence-based implementation and funding conditions for specified grant programs. Its funding provisions are not a universal payment rule for every clinic, insurer, or country. Ask the particular service what arrangement applies to you and request its current written explanation rather than assume a figure seen online is your entitlement.

If a program uses vouchers or prizes, ask what can be obtained, whether there are restrictions, and how the process is documented. Describe any concern about the format, including a history of gambling problems or discomfort with a chance-based element. The clinician can explain the chosen model and whether an appropriate alternative is available. Do not assume that every incentive arrangement is interchangeable.

How will results be verified and discussed?

When testing is part of the program, ask what is measured, how specimens are collected, and how results are interpreted. The clinical team should know about prescribed medicines and relevant health information. A test result should be explained within its limitations rather than treated as a complete diagnosis or a judgment about a person’s honesty.

Ask what happens if a result is unexpected, disputed, delayed, or unclear. Is further review or confirmation needed? Who explains the decision, and how can you raise a concern? The process should be understandable before a disagreement occurs. Do not stop a prescribed medicine on your own because you are worried about how a test might be interpreted.

Clarify how results affect the incentive schedule and the separate clinical plan. These are related decisions but not identical ones. An unexpected result may prompt a treatment discussion, further assessment, or additional support. It should not be assumed to answer every question about safety, diagnosis, or the appropriate level of care without clinical review.

What happens after a missed visit or return to use?

Ask the service to explain the rules before enrollment. What happens if you miss a scheduled visit, arrive late, or cannot provide the required verification? How are illness, transport failure, or a clinical emergency handled? A clear policy helps you understand the program and identify barriers that need attention in advance.

If substance use occurs, disclose it to the treating team so immediate health needs can be assessed. A change in incentives should not become the only response. There may be overdose risk, withdrawal concerns, medication interactions, or a worsening psychiatric condition. The team needs to evaluate those issues and explain any adjustment to care.

Ask whether ordinary clinical access continues when a target is not met. Essential assessment and appropriate treatment should be discussed on clinical grounds, separately from the incentive rules. If you feel that the process has become shaming or punitive, raise the concern with the program lead. A structured system can be transparent without treating a difficult episode as a moral failure.

How does CM fit the mental health plan?

The NIMH overview of co-occurring disorders supports treatment that addresses both substance use and mental health needs. CM may support a defined behavior while another intervention addresses depression, PTSD, bipolar disorder, anxiety, or a different condition. Ask which clinician is responsible for each part and how they communicate relevant changes with consent.

Our shared care plan guide explains how responsibilities can be made explicit. If severe depression makes attendance difficult, or a change in mental state affects participation, the response should include assessment of that problem. Repeating the incentive rules alone may not address the reason the arrangement has become unmanageable.

Medication for an established psychiatric or substance use condition should not be changed by an incentive administrator without appropriate prescribing authority. Bring concerns to the responsible clinician. A CM program should not require you to interpret medication effects or reconcile conflicting instructions alone. Ask how the service separates administrative tasks from clinical decisions.

Can the schedule work in your actual life?

Consider travel time, work, caregiving, mobility, and the predictability of appointments. A program can have an evidence-based design and still require practical adjustments or support for an individual to participate. Ask what assistance is available and whether another appropriate service offers a feasible arrangement. Do not assume that difficulty attending means you do not want treatment.

If digital tools are used, ask what device, connection, and privacy are required. Confirm how technical failures are handled and whom to contact. A broken phone, limited data plan, or lack of private space should be discussed before it becomes a repeated obstacle. The service should explain which parts can be completed remotely and which require attendance.

Ask about costs that are separate from the incentives. These may include clinical appointments, testing, travel, or other program fees. Obtain the relevant current terms from the provider or payer. An incentive should not obscure an expense or create an assumption that the entire treatment package is funded. The practical decision needs a clear view of both care and costs.

Who can see the information?

Ask how attendance, results, and incentive records are stored and who can access them. The service should explain the applicable confidentiality policy and its limits. Participation in CM does not automatically authorize disclosure to an employer, relative, or other outside party. If another organization is involved, clarify the information-sharing arrangement and consent before enrolling.

Discuss whether the incentive process is private within the service. You may not want other participants to know the details of your results or rewards. Ask how staff avoid unnecessary disclosure and how to report a concern. Transparency about the rules does not require public comparison between patients.

If a family member helps with transport or reminders, define that role separately. They do not need to become the person administering incentives or judging results unless a specific, clinically appropriate arrangement has been discussed and agreed. Support should remain realistic and respectful of each person’s boundaries.

What continues when incentives end?

Ask about the end of the program at the beginning. Which clinical treatments and practical supports continue? How will the team review progress and prepare for the change in structure? A fixed CM period should connect to ongoing care rather than end with an abrupt loss of all contact. Our care plan review guide helps frame that discussion.

Review the specific target and the broader outcomes separately. Has the relevant behavior changed? Are mental health symptoms adequately treated? Can you attend care, manage daily responsibilities, and obtain support when needed? A successful incentive record is useful information, but it does not settle every question about the next stage of treatment.

If the approach is not producing the intended benefit, ask what should be reassessed: the target, delivery, practical barriers, an unmet psychiatric need, or the overall level of care. The program should be able to explain its reasoning and the alternatives. CM is most understandable when its rules, clinical purpose, and connection to continuing treatment are all explicit.

Sources and further reading

Found a detail that has changed? Tell the editorial team.